Extracellular-Vesicle-Based Therapeutics in Neuro-Ophthalmic Disorders
International Journal of Molecular Sciences · 19.05.2023 · 24 (10) · 9006
DOI: 10.3390/ijms24109006 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, online erschienen am 19.05.2023. Verfasst von Hamed Massoumi und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA. Hauptthemen laut MEDLINE: Mesenchymal Stem Cells, Extracellular Vesicles. Die Arbeit wurde bisher 42-mal zitiert (Crossref) und nennt 146 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NEI NIH HHS, NCATS NIH HHS, NIH HHS.
Abstract (Originalsprache)
Extracellular vesicles (EVs) have been recognized as promising candidates for developing novel therapeutics for a wide range of pathologies, including ocular disorders, due to their ability to deliver a diverse array of bioactive molecules, including proteins, lipids, and nucleic acids, to recipient cells. Recent studies have shown that EVs derived from various cell types, including mesenchymal stromal cells (MSCs), retinal pigment epithelium cells, and endothelial cells, have therapeutic potential in ocular disorders, such as corneal injury and diabetic retinopathy. EVs exert their effects through various mechanisms, including promoting cell survival, reducing inflammation, and inducing tissue regeneration. Furthermore, EVs have shown promise in promoting nerve regeneration in ocular diseases. In particular, EVs derived from MSCs have been demonstrated to promote axonal regeneration and functional recovery in various animal models of optic nerve injury and glaucoma. EVs contain various neurotrophic factors and cytokines that can enhance neuronal survival and regeneration, promote angiogenesis, and modulate inflammation in the retina and optic nerve. Additionally, in experimental models, the application of EVs as a delivery platform for therapeutic molecules has revealed great promise in the treatment of ocular disorders. However, the clinical translation of EV-based therapies faces several challenges, and further preclinical and clinical studies are needed to fully explore the therapeutic potential of EVs in ocular disorders and to address the challenges for their successful clinical translation. In this review, we will provide an overview of different types of EVs and their cargo, as well as the techniques used for their isolation and characterization. We will then review the preclinical and clinical studies that have explored the role of EVs in the treatment of ocular disorders, highlighting their therapeutic potential and the challenges that need to be addressed for their clinical translation. Finally, we will discuss the future directions of EV-based therapeutics in ocular disorders. Overall, this review aims to provide a comprehensive overview of the current state of the art of EV-based therapeutics in ophthalmic disorders, with a focus on their potential for nerve regeneration in ocular diseases.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Ophthalmology and Visual Sciences, University of Illinois at Chicago, Chicago, IL 60612, USA.
- The Richard and Loan Hill Department of Biomedical Engineering, University of Illinois at Chicago, Chicago, IL 60607, USA.
- Wills Eye Hospital, Mid Atlantic Retina, Thomas Jefferson University, Philadelphia, PA 19107, USA.
- Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA.
ORCID-Profile: Sohil Amin, Bita Momenaei, Peiman Hematti
Förderung
- NEI NIH HHS
- NCATS NIH HHS
- NIH HHS
- National Center for Advancing Translational Sciences
- National Institutes of Health
- National Eye Institute
- United States Department of Defense
Zitieren
APA
Massoumi, H., Amin, S., Soleimani, M., Momenaei, B., Ashraf, M. J., Guaiquil, V. H., Hematti, P., Rosenblatt, M. I., Djalilian, A. R., & Jalilian, E. (2023). Extracellular-Vesicle-Based Therapeutics in Neuro-Ophthalmic Disorders. International Journal of Molecular Sciences, 24(10), 9006. https://doi.org/10.3390/ijms24109006
Vancouver
Massoumi H, Amin S, Soleimani M, Momenaei B, Ashraf MJ, Guaiquil VH, et al. Extracellular-Vesicle-Based Therapeutics in Neuro-Ophthalmic Disorders. International Journal of Molecular Sciences. 2023;24(10):9006. doi:10.3390/ijms24109006
BibTeX
@article{Massoumi2023,
author = {Massoumi, Hamed and Amin, Sohil and Soleimani, Mohammad and Momenaei, Bita and Ashraf, Mohammad Javad and Guaiquil, Victor H and Hematti, Peiman and Rosenblatt, Mark I and Djalilian, Ali R and Jalilian, Elmira},
title = {Extracellular-Vesicle-Based Therapeutics in Neuro-Ophthalmic Disorders},
journal = {International Journal of Molecular Sciences},
year = {2023},
volume = {24},
number = {10},
pages = {9006},
doi = {10.3390/ijms24109006}
}
EUVIMED